West Branch Capital’s Bio-Rad Laboratories Class A BIO Stock Holding History

West Branch Capital’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23	Closed	-$5.55K	–	455
2025 Q2	$5.55K	Hold	23	–	–	﹤0.01%	321
2025 Q1	$5.6K	Hold	23	–	–	﹤0.01%	333
2024 Q4	$7.56K	Hold	23	–	–	﹤0.01%	298
2024 Q3	$7.7K	Hold	23	–	–	﹤0.01%	296
2024 Q2	$6.28K	Hold	23	–	–	﹤0.01%	315
2024 Q1	$7.96K	Hold	23	–	–	﹤0.01%	293
2023 Q4	$7.43K	Hold	23	–	–	﹤0.01%	301
2023 Q3	$8.24K	Hold	23	–	–	﹤0.01%	291
2023 Q2	$8.72K	Hold	23	–	–	﹤0.01%	294
2023 Q1	$11K	Hold	23	–	–	0.01%	281
2022 Q4	$9.67K	Hold	23	–	–	0.01%	287
2022 Q3	$10K	Hold	23	–	–	0.01%	282
2022 Q2	$11K	Hold	23	–	–	0.01%	265
2022 Q1	$13K	Hold	23	–	–	0.01%	267
2021 Q4	$17K	Hold	23	–	–	0.01%	274
2021 Q3	$17K	Hold	23	–	–	0.01%	253
2021 Q2	$15K	Buy	+23	New	+$14K	0.01%	279

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

West Branch Capital's BIO Position: Q3 2025 in Review

West Branch Capital sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2025, closing a stake of 23 shares — an estimated $5.55K sold.

West Branch Capital first reported a position in BIO in Q2 2021 and held it in 17 quarters. The position peaked at $17K in Q4 2021. 397 funds tracked by Wall St. Rank hold BIO as of Q3 2025.

West Branch Capital reported no remaining Bio-Rad Laboratories Class A position as of Q3 2025 after selling out during the quarter.
West Branch Capital sold 23 Bio-Rad Laboratories Class A shares in Q3 2025, an estimated $5.55K.
West Branch Capital first reported a position in Bio-Rad Laboratories Class A in Q2 2021 and held it in 17 quarters.
West Branch Capital's Bio-Rad Laboratories Class A position peaked at $17K in Q4 2021.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2025.

Based on West Branch Capital's 13F filing for Q3 2025, filed 21 Oct 2025.